CATALOGO DEI PRODOTTI DELLA RICERCA

MELISI, Davide
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.123
EU - Europa 3.789
AS - Asia 1.997
SA - Sud America 33
AF - Africa 20
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.979
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.094
CN - Cina 1.308
GB - Regno Unito 1.129
SG - Singapore 534
SE - Svezia 502
IT - Italia 478
RU - Federazione Russa 370
IE - Irlanda 359
FR - Francia 320
DE - Germania 258
FI - Finlandia 202
UA - Ucraina 70
VN - Vietnam 39
CA - Canada 27
JP - Giappone 26
NL - Olanda 22
BE - Belgio 20
TG - Togo 17
BR - Brasile 15
CH - Svizzera 12
HK - Hong Kong 12
KR - Corea 12
AU - Australia 11
ID - Indonesia 11
CL - Cile 10
IN - India 10
TR - Turchia 9
CZ - Repubblica Ceca 7
IR - Iran 7
SA - Arabia Saudita 6
AT - Austria 5
PE - Perù 5
PT - Portogallo 5
BG - Bulgaria 4
EU - Europa 4
LK - Sri Lanka 4
PL - Polonia 4
AM - Armenia 3
AZ - Azerbaigian 3
BY - Bielorussia 3
RO - Romania 3
AL - Albania 2
DK - Danimarca 2
EC - Ecuador 2
EE - Estonia 2
IL - Israele 2
KZ - Kazakistan 2
LT - Lituania 2
LV - Lettonia 2
PA - Panama 2
PK - Pakistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AR - Argentina 1
EG - Egitto 1
GE - Georgia 1
HU - Ungheria 1
IM - Isola di Man 1
KG - Kirghizistan 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 9.979
Salva come PNG Salva come JPEG
Città #
Southend 1.033
Chandler 841
Jacksonville 488
Singapore 431
Woodbridge 400
Ashburn 375
Dublin 359
Ann Arbor 268
Beijing 192
Jinan 160
Houston 134
Lawrence 132
Princeton 132
Verona 127
Wilmington 126
Shenyang 97
Nanjing 88
Helsinki 72
Hebei 66
Tianjin 55
New York 52
Changsha 46
Sindelfingen 45
Haikou 44
Zhengzhou 43
Taiyuan 39
Hangzhou 35
Redwood City 35
Ningbo 31
Milan 29
Nanchang 28
Taizhou 27
Guangzhou 26
Fuzhou 25
Seattle 23
Washington 23
Redmond 22
Kent 21
Brussels 20
Dong Ket 20
Boardman 19
Jiaxing 19
Lomé 17
Norwalk 17
Rome 17
Tokyo 17
Toronto 17
Los Angeles 15
Santa Clara 15
Bologna 14
Dallas 13
Lanzhou 13
Dongguan 12
Hong Kong 11
Zurich 11
Frankfurt am Main 10
Seoul 10
Amsterdam 9
Chicago 9
Jakarta 9
San Francisco 9
Fairfield 8
Dearborn 7
Lancaster 7
Xiangfen 7
Clearwater 6
Moscow 6
Elora 5
Glasgow 5
Lima 5
Markgröningen 5
Nürnberg 5
San Diego 5
Treviso 5
Acireale 4
Auburn Hills 4
Brescia 4
Cagliari 4
Colombo 4
Falls Church 4
Lille 4
Lisbon 4
Monza 4
Prague 4
Riyadh 4
Sofia 4
Sydney 4
Vicenza 4
Vienna 4
Baku 3
Canberra 3
Chaoyang 3
Düsseldorf 3
Falkenstein 3
Frignano 3
Genoa 3
Lappeenranta 3
London 3
Marsala 3
Melbourne 3
Totale 6.662
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 210
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 149
Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. 140
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 138
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 126
NF-κB as a target for pancreatic cancer therapy. 115
TGF-beta-activated Kinase 1 (TAK1) is a therapeutic target modulating pancreatic cancer chemoresistance 111
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 111
PEROXIREDOXIN-2: A NOVEL REGULATOR OF IRON HOMEOSTASIS IN INEFFECTIVE ERYTHROPOIESIS 108
Anti- VEGF treatment resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype 107
Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT 107
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma 106
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 104
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 103
Pancreatic ductal adenocarcinoma cell lines display a plastic ability to bi‑directionally convert into cancer stem cells 102
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 102
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 101
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 101
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 101
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 100
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 99
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 98
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 96
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 94
R1507, the human monoclonal antibody targeting the Insulin-like Growth Factor Receptor (IGF-1R), in combination with cetuximab can reverse acquired resistance to cetuximab in pancreatic and colon cancer models 94
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 93
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 93
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 91
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 90
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 89
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 88
Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results 88
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 88
A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer 87
Correlation of MR features and histogram-derived parameters with aggressiveness and outcomes after resection in pancreatic ductal adenocarcinoma 87
Angiogenesis: A target for cancer therapy. 85
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 85
Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy 85
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 83
The development of PARP as a successful target for cancer therapy 83
Pancreatic Cancer: between bench and bedside. 83
Combination of a selective cyclooxygenase-2 inhibitor with EGFR tyrosine kinase inhibitor ZD1839 (‘Iressa’) and Protein Kinase A antisense causes a cooperative antitumor and antiangiogenic effect 82
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 82
EMT and Treatment Resistance in Pancreatic Cancer 82
Plasma Interleukin-8 is a biomarker for TAK1 activation and predicts resistance to nanoliposomal irinotecan in patients with gemcitabine-refractory pancreatic cancer 82
Gefitinib ('Iressa, ZD1839') and a second generation antisense targeting murine double minute 2 (Mdm2) synergistically inhibit tumor growth and angiogenesis in hormone-refractory prostate cancer 81
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers 80
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinib ('Iressa') cooperatively inhibits growth and angiogenic factor expression in breast and prostate carcinoma cells. 80
Data demonstrating the role of peroxiredoxin 2 as important anti-oxidant system in lung homeostasis. 79
Zoledronic acid (ZOMETA) in combination with a COX-2 inhibitor and gefitinb ('Iressa, ZD1839') cooperatively inhibits growth and angiogenic factor expression and secretion in breast and prostate carcinoma cells 78
Rare secondary tumors of the pancreas 78
Modulating TAK1 expression inhibits YAP and TAZ oncogenic functions in pancreatic cancer 78
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 78
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research 77
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. 76
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib 76
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 75
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 75
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data 75
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 75
Human cancer cells with acquired resistance to anti-EGFR therapy are inhibited by VEGF- and EGFR-receptors tyrosine kinase inhibitor ZD6474 74
A novel modified CpG inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan in colon cancer xenografts. 74
TGF-beta activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) 74
Novel Toll-like receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancer 74
The curious case of Gαs gain-of-function in neoplasia 74
Histogram analysis of magnetic resonance images: evaluation of intra-tumoral heterogeneity and correlation with pathological findings in solid pancreatic tumors. 74
Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer 74
The novel poly(ADP-ribose) polymerase (PARP)-1 inhibitor, BSI-401, has anti tumor activity and potentiates oxaliplatin cytotoxic activity in human pancreatic cancer 73
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 73
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial 72
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis 71
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 71
Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation 71
CT texture analysis of ductal adenocarcinoma downstaged after chemotherapy 71
Toll-Like Receptor 9 Agonists for Cancer Therapy 71
Key cancer cell signal transduction pathways as therapeutic targets. 70
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 69
Novel anticancer drugs TLR9 agonists interfere with EGFR signaling and potently synergies with EGFR inhibitors and with bevacizumab in wild type and cetuximab-resistant colon cancer xenografts 69
TGF-beta-activated kinase 1 (TAK1) is an in vivo druggable target for reverting pancreatic cancer chemoresistance 69
Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. 68
Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus 68
MEKK3 Sustains EMT and Stemness in Pancreatic Cancer by Regulating YAP and TAZ Transcriptional Activity 68
Serum CA 19-9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC). 67
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world 67
The role of the oncologist in the diagnosis and management of malignant cystic neoplasms 66
TAK-ing aim at chemoresistance: The emerging role of MAP3K7 as a target for cancer therapy 64
Rationale and clinical use of multitargeting anticancer agents. 63
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 62
ESGAR 2018 Book of Abstracts 62
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. 61
The protein kinase C beta antagonist enzastaurin (LY317615.HCl) inhibits cancer cell growth by multiple mechanisms and is active in EGFR inhibitors-resistant cancer cells 61
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 61
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 60
Pathologic angiogenesis in the bone marrow of humanized sickle cell mice is reversible by blood transfusion 60
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 60
Targeting transforming growth factor beta (TGFbeta) type I receptor kinase activity: a therapeutic approach to suppress metastatic processes in human pancreatic cancer (HPC) 58
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 58
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 58
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma 56
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 54
Totale 8.380
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.732
article - articoli 33.441
book - libri 0
conference - conferenze 5.272
curatela - curatele 0
other - altro 270
patent - brevetti 0
selected - selezionate 0
volume - volumi 749
Totale 79.464
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020566 0 0 0 0 0 71 82 54 61 94 67 137
2020/20211.111 131 191 33 138 129 134 8 69 34 58 107 79
2021/20221.221 87 433 13 167 15 15 9 62 38 22 68 292
2022/20232.311 180 234 221 357 209 553 28 138 293 23 49 26
2023/20241.331 43 101 94 123 164 183 116 166 15 71 198 57
2024/20251.179 167 191 110 510 138 63 0 0 0 0 0 0
Totale 10.155